Next, we explored the detailed pathogenesis of SCA19/22 with KCND3 loci mutation by inducing pluripotent stem cells (iPSCs) derived from patients, which may serve as drug targets for developing potential SCA19/22 therapeutics. The gene discussed is KCND3; the disease is spinocerebellar ataxia type 19/22.